Investigational New Drugs

, Volume 13, Issue 4, pp 337–342

A phase II study of thioTEPA in children with recurrent solid tumor malignancies: a Children's Cancer Group study

  • J. Russell Geyer
  • Frank M. Balis
  • Mark D. Krailo
  • Richard Heideman
  • Emmett Broxson
  • Judith K. Sato
  • David Poplack
  • W. Archie Bleyer
Phase II Studies

DOI: 10.1007/BF00873141

Cite this article as:
Geyer, J.R., Balis, F.M., Krailo, M.D. et al. Invest New Drugs (1995) 13: 337. doi:10.1007/BF00873141

Summary

A Phase II study of thioTEPA was performed by the Children's Cancer Group. ThioTEPA was administered intravenously every three weeks, at a dose of 65 mg/m2. Pediatric patients with recurrent sarcomas were targeted, but patients with other tumor diagnoses were also eligible. Toxicity was primarily hematopoietic, with thrombocytopenia being predominant. ThioTEPA did not demonstrate significant activity in the target tumor groups evaluated.

Key words

thioTEPAalkylating agentssarcomaschemotherapy

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • J. Russell Geyer
    • 1
  • Frank M. Balis
    • 2
  • Mark D. Krailo
    • 3
  • Richard Heideman
    • 4
  • Emmett Broxson
    • 5
  • Judith K. Sato
    • 6
  • David Poplack
    • 7
  • W. Archie Bleyer
    • 8
  1. 1.Children 's Hospital and Medical CenterUniversity of WashingtonSeattle
  2. 2.National Cancer Institute-NIHBethesda
  3. 3.University of Southern California School of MedicineLos Angeles
  4. 4.St. Jude Children's Research HospitalMemphis
  5. 5.Wright Patterson AFBDayton
  6. 6.Childrens Hospital of Los AngelesLos Angeles
  7. 7.Texas Children's Cancer CenterHouston
  8. 8.M.D. Anderson Cancer CenterUniversity of TexasHoustonUSA